Pharma channel feed – Endpoints News

Pharma channel feed

With hep C franchises languishing, Merck’s MK-3682 goes from blockbuster to bomb

9 years ago

Genmab outlines a megablockbuster future for itself and J&J as Darzalex gains market traction

9 years ago

The FDA opens an inside track to let Novartis race ahead on Zykadia as Roche rivalry heats up

9 years ago

Big Pharma CEOs push hard for tax reform and a proposed border levy

9 years ago

2016 went out like a lamb in the biopharma M&A world. Will it roar back in 2017? Plus, top 10 deals

9 years ago

Pfizer shortens comeback campaign for armed antibody inotuzumab, lands quick FDA review

9 years ago

Gilead bags Sarepta's priority review voucher for a discount, paying $125M

9 years ago

An FDA reform agenda: What would Commissioner Scott Gottlieb do in his first six months?

9 years ago

After steering through a controversy over soaring price of naloxone, FDA rejects Amphastar’s intranasal version

9 years ago

Gilead offloads a PhII-ready addiction therapy to an upstart which knows this drug well

9 years ago

In the hunt for a megablockbuster, Celgene plans FDA filing in wake of PhIII win for ozanimod in MS

9 years ago

Alexion shelves an early-stage Sanfilippo B drug, writes off $85M

9 years ago

PhRMA disses Marathon CEO—and PhRMA board member—Jeff Aronin after latest price gouging controversy

9 years ago

Valeant gets an FDA OK for new psoriasis drug brodalumab — but there’s a big catch

9 years ago

Patent board tells CRISPR scientists to back off from a nasty fight over gene editing tech

9 years ago

The E100: Biotech execs are bullish about 2017, but fret about drug pricing and the FDA under Trump

9 years ago

Agenus pockets a fast $80M in cash and hands the R&D keys over to Incyte

9 years ago

Marathon CEO tries to call a time out on controversy as lawmakers rip into $89K deflazacort price

9 years ago

Activists slam Immunomedics’ $2B deal with Seattle Genetics in the middle of a proxy war

9 years ago

The scoop: Marathon’s R&D program for Duchenne MD drug likely came in at a bargain basement price

9 years ago

Seattle Genetics grabs Immunomedics’ tumor drug in $2B deal, shooting for a quick OK

9 years ago

Neurocrine adds a Parkinson’s drug to its late-stage pipeline in $145M deal

9 years ago

Marathon's cheap, old steroid breezes through the FDA for Duchenne MD, and gets priced at $89K

9 years ago

Sanofi, Regeneron win a crucial stay of execution on Praluent

9 years ago

First page Previous page 332 333 334335336 337 338 Next page Last page